Financial Performance - The company's audited net profit for 2021 was CNY 85.0134 million, with a cumulative undistributed profit of -CNY 156 million as of December 31, 2021, resulting in no profit distribution to shareholders[7]. - Total operating revenue for 2021 reached CNY 1.535 billion, representing a 16.41% increase compared to CNY 1.319 billion in 2020[25]. - The net profit attributable to shareholders of the listed company was CNY 155.32 million, a significant recovery from a loss of CNY 126.86 million in 2020[25]. - The net cash flow from operating activities for 2021 was CNY 320.96 million, reflecting a 31.35% increase from CNY 244.35 million in 2020[25]. - The net profit after deducting non-recurring gains and losses was CNY 55.05 million, compared to a loss of CNY 211.75 million in the previous year[25]. - The company did not implement capital reserve transfers to increase share capital or other forms of distribution due to negative retained earnings[7]. - The net profit attributable to shareholders of the listed company turned from a loss to a profit, mainly due to an increase in revenue and a reduction in goodwill impairment loss of 265 million yuan from the previous year[27]. - Basic earnings per share improved to 0.33 yuan, compared to a loss of 0.27 yuan in the previous year[27]. - The weighted average return on net assets increased by 8.28 percentage points to 4.52%[27]. - The company achieved operating revenue of CNY 1.535 billion, an increase of 16.41% compared to the previous year[77]. - The net profit attributable to shareholders was CNY 155.32 million, with a net profit of CNY 55.05 million after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year[77]. Research and Development - Research and development investment accounted for 9.55% of revenue, significantly higher than the industry average in 2020[37]. - The company invested CNY 146.70 million in R&D in 2021, representing 9.55% of total revenue, which is above the industry average[45]. - The number of R&D personnel increased to 206 in 2021, accounting for 9.23% of the total workforce[45]. - The company completed 54 out of 116 R&D projects during the reporting period, including 48 projects related to stem cell research and product development[45]. - The company has established a comprehensive research and development system, collaborating with renowned hospitals and experts to advance stem cell clinical projects and drug development[69]. - The company aims to enhance R&D capabilities and improve operational efficiency across its precision medical industry chain[65]. - The company is committed to advancing research in stem cell technology, as indicated by its involvement in national key research projects[58]. - The company has developed a leading antibody research and production platform, offering a wide range of protein products and solutions in the research field[69]. Market Expansion and Strategy - The company aims to strengthen its position in the cell and gene therapy sector, which is seen as a key growth area in the biopharmaceutical industry[37]. - The company is actively collaborating with agents, insurance, and banking clients to enhance its market presence and professional image in adult cell storage[59]. - The company is focused on expanding its market presence in both domestic and international pathology diagnosis markets[63]. - The company is exploring innovative cooperation models with top-tier hospitals to enhance industrial development[76]. - The company is expanding its market presence in Asia, targeting a 10% market share by the end of the next fiscal year[163]. - The company plans to enhance its immune cell storage business as a new growth point, focusing on product design, agency policies, and optimizing online business systems, particularly in mature markets like Shanghai, Zhejiang, Hubei, and Henan[134]. Clinical and Product Development - The company is advancing clinical approval for two targeted drug screening kits for lung and colorectal cancer, with nearly 50% of sample enrollment completed[42]. - The company is conducting a clinical trial for mesenchymal stem cells, with 31 out of 36 participants enrolled for the treatment of chronic periodontitis[48]. - The CNCT19 cell injection, developed by a subsidiary, has entered Phase II clinical trials for acute lymphoblastic leukemia and non-Hodgkin lymphoma, and received orphan drug designation from the FDA[48]. - The company has successfully obtained clinical research approval for umbilical cord mesenchymal stem cells to treat refractory diabetic peripheral neuropathy[48]. - The company has completed the filing of multiple clinical research projects in collaboration with various hospitals, enhancing its research capabilities[76]. Financial Management and Governance - The total remuneration paid to all directors, supervisors, and senior management during the reporting period amounted to CNY 12.7026 million[177]. - The company implemented a director and supervisor allowance system, with the remuneration plan for senior management approved by the board's remuneration and assessment committee[177]. - The company faced regulatory penalties, including a warning letter issued by the China Securities Regulatory Commission to the former actual controller for non-operating fund occupation[178]. - The company has maintained compliance with its articles of association regarding profit distribution policies[197]. - The independent directors have provided their opinions on the profit distribution plan, confirming its legality and compliance[197]. Operational Efficiency - The company has optimized its quality management system to enhance product quality and operational efficiency, including improvements in NK cell preparation processes[49]. - The establishment of a financial shared service center is underway to enhance operational efficiency and risk management[50]. - The online platform for the life bank has been upgraded, resulting in improved operational efficiency and customer binding rates[50]. - The company is focused on operational efficiency improvements to strengthen its industry position as it expands its adult cell storage business from broad coverage to targeted key regions[59]. Industry Trends and Challenges - The biopharmaceutical industry is witnessing a shift towards more standardized practices and increased emphasis on endogenous innovation, with significant advancements in new technologies and drug approvals[123]. - The domestic clinical research landscape for stem cell therapy is robust, with 111 projects registered, covering various medical categories[126]. - The in vitro diagnostic market in China is expected to grow rapidly due to economic development, healthcare reform, and increasing disposable income, with significant competition emerging[144]. - The company faces risks related to industry policies, particularly in advanced technologies like stem cells and gene testing, which may be subject to future regulatory changes[140].

Financial Performance - The company's operating revenue for Q3 2021 was ¥391,700,257.34, representing an increase of 11.95% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2021 was ¥80,118,557.13, reflecting a significant increase of 54.74% year-over-year[7]. - The basic earnings per share for Q3 2021 was ¥0.17, up by 54.55% year-over-year[10]. - Net profit for the third quarter of 2021 was ¥194,586,517.04, compared to ¥133,093,977.65 in the previous year, indicating a growth of 46.1%[33]. - The company reported a profit before tax of ¥259,681,320.22, up from ¥170,448,436.72, representing a growth of 52.2%[33]. - Total comprehensive income for the period was CNY 186,621,508.15, a decrease from CNY 283,669,410.36 in the previous period[35]. - Basic and diluted earnings per share increased to CNY 0.41 from CNY 0.28 year-over-year[35]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,180,605,540.72, an increase of 6.17% from the end of the previous year[10]. - The total assets of the company were reported at ¥5,180,605,540.72, an increase from ¥4,879,569,536.17 year-over-year[24]. - Current liabilities totaled ¥1,382,441,046.85, compared to ¥1,300,015,430.19 in the previous year, showing an increase of approximately 6.3%[24]. - The company's total liabilities increased to ¥1,493,581,632.30 from ¥1,377,191,804.90, showing a rise of 8.4%[26]. - The total equity attributable to shareholders of the parent company rose to ¥3,586,855,067.12, up from ¥3,396,348,979.10, marking an increase of 5.6%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥232,588,634.00, reflecting a year-over-year increase of 53.40%[10]. - Cash inflow from operating activities totaled CNY 1,245,397,088.82, up from CNY 1,060,592,301.77 in the previous year[39]. - Net cash flow from operating activities was CNY 232,588,634.00, compared to CNY 151,618,311.80 in the same period last year[39]. - Cash outflow from investment activities was CNY 164,292,903.89, significantly lower than CNY 735,223,631.40 in the previous year[39]. - Net cash flow from investment activities was negative CNY 92,456,340.77, compared to a positive CNY 306,040,337.65 in the previous year[39]. - Total cash inflow from financing activities was CNY 692,100.00, down from CNY 35,876,865.61 in the previous year[39]. - Net cash flow from financing activities was negative CNY 21,937,567.81, compared to negative CNY 72,575,923.72 in the previous year[39]. Shareholder Information - The company reported a total of 38,203 common shareholders at the end of the reporting period[14]. - The major shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares[14]. Investments and Expenses - Research and development expenses for the third quarter were ¥102,165,541.66, compared to ¥93,035,969.44 in the same quarter of 2020, reflecting a 9.1% increase[29]. - The company attributed the increase in net profit to the fair value gains from the fund shares held by its foreign subsidiary Aceso[13]. - Total operating costs amounted to ¥1,000,760,328.15, up from ¥857,674,929.78, reflecting a significant increase in expenses[29]. Other Financial Metrics - The weighted average return on equity for Q3 2021 was 2.22%, an increase of 0.79 percentage points compared to the same period last year[10]. - The deferred income tax liabilities increased significantly to ¥35,481,489.27 from ¥14,405,856.03, indicating a rise of 146.5%[26]. - The company recorded a decrease in other comprehensive income after tax, amounting to -¥7,965,008.89, compared to an increase of ¥150,575,432.71 in the previous year[33]. - The company reported a decrease in inventory, which stood at ¥217,958,041.29, down from ¥222,395,516.19[21]. - The company's goodwill remained stable at ¥722,634,814.15, unchanged from the previous year[24].

Financial Performance - The company achieved operating revenue of RMB 768.10 million in the first half of 2021, representing a growth of 23.99% compared to the same period last year [20]. - The net profit attributable to shareholders of the listed company was RMB 110.70 million, an increase of 36.12% year-on-year [20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 72.45 million, showing a significant growth of 207.12% compared to the previous year [20]. - The net cash flow from operating activities was RMB 122.43 million, up 44.75% from the same period last year [20]. - Basic earnings per share for the reporting period were RMB 0.24, up 41.18% from RMB 0.17 in the same period last year [21]. - The weighted average return on net assets increased to 3.16%, up by 0.79 percentage points compared to the previous year [21]. - The company reported a non-recurring profit of approximately RMB 38.25 million, with government subsidies contributing RMB 17.70 million and other non-operating income totaling RMB 2.17 million [25]. - The company achieved a revenue of 768.1 million RMB, representing a year-on-year growth of 23.99% [52]. - The net profit attributable to shareholders reached 110.7 million RMB, an increase of 36.12% compared to the previous year [52]. - The net profit after deducting non-recurring gains and losses was 72.5 million RMB, showing a significant growth of 207.12% year-on-year [52]. Business Operations - The company focuses on "precision medicine" with a business model that includes direct sales and a nationwide marketing network, enhancing R&D capabilities and product offerings [27]. - The precision prevention business includes newborn stem cell storage and adult cell storage, with significant roles in treating blood system diseases and immune regulation [31]. - The precision diagnosis segment offers a range of products and services, including in vitro diagnostic reagents and genetic testing, covering various diseases such as tumors and cardiovascular conditions [32]. - The precision treatment business encompasses stem cell and immune cell therapies, with ongoing clinical project registrations and drug development efforts [33]. - The company operates the Tianjin umbilical cord blood stem cell bank, which has provided 2,760 units of cord blood for disease treatment as of June 2021 [40]. - The company has established a self-cell resource bank covering two-thirds of the country, storing various types of stem cells [40]. - The company’s CAR-T cell therapy product CNCT19 has entered clinical phase II for acute lymphoblastic leukemia and non-Hodgkin lymphoma [43]. - The company’s subsidiary has developed a tumor-targeted drug gene testing kit, which is currently in clinical trial stages [43]. - The company’s subsidiary, Zhongyuan Weikang, has exclusive cooperation with AGNEA for lung cancer and colorectal cancer targeted drug gene testing in China [43]. Market and Regulatory Environment - Recent policies, including the "three-child policy," are expected to positively impact the newborn storage business by potentially increasing birth rates [37]. - The revised Medical Device Supervision and Administration Regulations are set to enhance innovation and quality in the medical device industry, benefiting the in vitro diagnostic market [38]. - The government is working on regulations for biomedical new technologies, which will provide clearer guidelines for stem cell clinical research and applications, supporting industry development [39]. - The in vitro diagnostic market in China has reached a scale of over 100 billion RMB, with a growth rate exceeding 15% post-2020 pandemic [41]. - The domestic biochemical diagnostic reagent import substitution rate has surpassed 60%, with over 200 domestic manufacturers competing in the market [43]. Research and Development - The company’s R&D expenses increased by 27.86% to 69.9 million RMB compared to the previous year [58]. - The company has completed 6 clinical research project filings for stem cell therapy, including projects for hepatitis B cirrhosis and chronic kidney disease [43]. - The company plans to collaborate with Peking University Third Hospital on reproductive health and sports medicine research projects [43]. Financial Position and Assets - The total assets of the company at the end of the reporting period were RMB 5,173.29 million, an increase of 6.02% compared to the end of the previous year [20]. - The net assets attributable to shareholders of the listed company were RMB 3,625.68 million, reflecting a growth of 6.75% year-on-year [20]. - The company reported total current assets as of June 30, 2021, amounted to CNY 1,997,714,317.90, an increase from CNY 1,915,103,978.70 as of December 31, 2020, reflecting a growth of approximately 4.2% [136]. - Cash and cash equivalents were reported at CNY 1,107,763,440.48, up from CNY 1,060,319,378.62, indicating an increase of about 4.4% [136]. - The company’s long-term equity investments increased by 20.24% to CNY 248,523,728.20 [63]. - The company reported a net loss of ¥600,149,047.78, an improvement from a loss of ¥710,853,180.48 in the previous period [140]. Shareholder and Governance - The total number of common shareholders as of the end of the reporting period is 36,442 [125]. - The largest shareholder, Tianjin Development Zone, holds 12.14% of shares, with a total of 56,787,503 shares [125]. - The company has established principles for related party transactions to ensure fairness and protect the interests of minority shareholders [101]. - The company guarantees that any future business opportunities that may compete with its main business will be promptly communicated to the company, ensuring priority for the company in such cases [99]. - The company has committed to avoiding any form of direct or indirect competition with its subsidiaries, ensuring no similar business activities will be conducted in the future [106]. Legal and Compliance Issues - The company is involved in significant litigation regarding the transfer of 8,000 acres of state-owned land use rights, with a court ruling requiring repayment of CNY 71.21 million [115]. - A civil mediation agreement from December 2018 mandates a payment of CNY 30 million for a share transfer, of which only CNY 1 million has been received, leaving a balance of CNY 29 million unpaid [115]. - The company has not faced any major penalties or compliance issues during the reporting period [118]. Risks and Challenges - The company faces industry policy risks due to the advanced technology in its main business areas, including stem cells and gene testing, which may be subject to future regulations [84]. - Talent retention is a concern as the company requires skilled personnel across various fields, and there is a risk of core personnel turnover impacting development [84]. - The company operates globally with branches in the US, Germany, and China, exposing it to foreign exchange risks due to currency fluctuations affecting financial performance [84].

证券代码：600645 证券简称：中源协和 公告编号：2021-018 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2021年5月19日（星期三）15:00-16:30 ●召开方式：网络方式召开 ● 投 资 者 在 接 待 日 活 动 召 开 前 登 录 全 景 网 互 动 平 台 中 源 协 和 页 面 （https://ir.p5w.net/c/600645.shtml）进行提问，或在召开当天15:00-16:30 登录"全景·路演天下"（http://rs.p5w.net）参与本次互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2021年4月24 日发布了2020年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2021年5月19日（星期三）15:00-16:30 方式：网络方式召开 ...

Financial Performance - Net profit attributable to shareholders increased by 644.70% to CNY 45,553,625.54 year-on-year[12] - Operating revenue rose by 32.44% to CNY 366,683,497.82 compared to the same period last year[12] - Basic and diluted earnings per share both reached CNY 0.10, up 900.00% from CNY 0.01 in the previous year[12] - The significant increase in net profit was primarily due to the full waiver of the "PPP loan" approved by the SBA during the reporting period[18] - The net profit for Q1 2021 was ¥45,810,334.85, compared to a net profit of ¥5,889,050.84 in Q1 2020, representing a significant increase[45] - The comprehensive income total for Q1 2021 was ¥198,919,770.59, compared to ¥12,329,379.82 in Q1 2020, indicating strong growth[45] Cash Flow - Net cash flow from operating activities surged by 1,491.49% to CNY 49,151,166.35 year-on-year[12] - Cash flow from operating activities for Q1 2021 was ¥49,151,166.35, a significant increase from ¥3,088,365.70 in Q1 2020[55] - The net cash flow from operating activities for Q1 2021 was -8,926,947.28 RMB, an improvement from -20,879,853.57 RMB in Q1 2020[57] - Total cash inflow from operating activities was 58,829,999.63 RMB, compared to 46,385,745.41 RMB in the same period last year, representing a 26.8% increase[57] Assets and Liabilities - Total assets increased by 5.05% to CNY 5,126,007,661.74 compared to the end of the previous year[12] - Total liabilities reached ¥1,424,710,159.88, up from ¥1,377,191,804.90, marking a growth of around 3.44%[33] - Current liabilities rose to ¥1,324,843,654.87, compared to ¥1,300,015,430.19, indicating an increase of approximately 1.91%[31] - The company’s long-term borrowings decreased by 28.56% compared to the beginning of the year, due to the full exemption of previously applied loans[22] - The total assets as of Q1 2021 amounted to 4,879,569,536.17 RMB, a decrease from 4,935,894,374.98 RMB in the previous year[61] Shareholder Information - The number of shareholders at the end of the reporting period was 35,892[15] - The total equity attributable to shareholders increased to ¥3,595,012,040.38 from ¥3,396,348,979.10, reflecting a growth of about 5.85%[33] Expenses - Sales expenses increased by 47.93% year-on-year, mainly due to increased operating income during the reporting period[25] - Financial expenses decreased significantly by 1053.00% year-on-year, primarily due to increased interest income from deposits[25] - Research and development expenses for Q1 2021 were ¥29,769,464.49, slightly up from ¥27,897,123.35 in Q1 2020[44] Government Support - The company received government subsidies amounting to CNY 13,133,781.52, which are included in the current profit and loss[15] - Other income increased by 1690.68% year-on-year, mainly due to the full exemption of the "U.S. PPP Guarantee Program Loan" approved by the SBA[25] Investment Activities - Investment activities generated a net cash outflow of approximately 69.07 million, a decrease of 191.29% year-on-year, mainly due to structural deposits[28] - The company reported investment income losses of ¥2,564,779.24 in Q1 2021, compared to a gain of ¥2,314,299.99 in Q1 2020, indicating a downturn in investment performance[50] Changes in Financial Position - Other receivables increased by 142.83% to CNY 68,566,787.22 compared to the beginning of the year[19] - Other receivables rose significantly to ¥173,528,094.16 from ¥131,063,690.60, indicating an increase of approximately 32.5%[37] - Cash and cash equivalents decreased to ¥449,653,162.93 from ¥486,133,836.39, a decline of approximately 7.51%[33]

Financial Performance - In 2020, the company's operating revenue was approximately RMB 1.32 billion, a decrease of 4.90% compared to RMB 1.39 billion in 2019[25]. - The net profit attributable to shareholders of the listed company for 2020 was a loss of approximately RMB 126.86 million, a decline of 355.29% compared to a profit of RMB 49.69 million in 2019[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately RMB 211.75 million, a decrease of 844.60% compared to a profit of RMB 28.44 million in 2019[25]. - Basic earnings per share for 2020 was -0.27 yuan, a decrease of 345.45% compared to 2019[26]. - Net profit attributable to shareholders decreased by 355.29% year-on-year, primarily due to a goodwill impairment loss of 265 million yuan[26]. - The company reported a cumulative undistributed profit of approximately RMB -227 million as of December 31, 2020, leading to no profit distribution to shareholders[6]. - The company has indicated that it will not implement capital reserve transfers to increase share capital or other forms of distribution due to the negative cumulative undistributed profit[6]. - The company reported a net profit margin of 0% for the years 2018, 2019, and 2020, indicating no profit distribution to shareholders[121]. Cash Flow and Investments - The net cash flow from operating activities for 2020 was approximately RMB 244.35 million, an increase of 1.19% compared to RMB 241.49 million in 2019[25]. - The company’s cash and cash equivalents increased by 67.85% compared to the beginning of the period, primarily due to the maturity of structured deposits[50]. - The company reported a significant improvement in cash flow from investment activities, with a net cash inflow of 308.09 million RMB, compared to a net outflow of 555.14 million RMB in the previous year[68]. - Cash flow from investing activities saw a significant increase of 155.50%, totaling ¥308,090,854.44, primarily due to the maturity of structured deposits[85]. - The company recognized an investment income of ¥43,300,143.33 from its subsidiary's investment in Aceso Biotech Venture Fund[87]. Business Operations and Strategy - The company operates in the "precision medicine" industry, focusing on cell detection preparation and storage, in vitro diagnostic materials, and gene testing services[36]. - The company has established cell resource banks across over 2/3 of the regions and 3/4 of the population in China, providing extensive coverage for stem cell detection and preparation services[36]. - The company has diversified its business model to include both newborn and adult cell storage services, catering to health-conscious adults and research institutions[36]. - The company aims to enhance its core businesses in cell storage and in vitro diagnostic reagents, focusing on expanding product lines and increasing R&D investment[111]. - The company will continue to enrich its cell storage offerings, including various types of stem cells and immune cells, while expanding its diagnostic testing products[111]. - The company is committed to promoting the clinical application of cell therapies and advancing related product development in collaboration with top-tier hospitals[111]. Research and Development - The company continued to invest in R&D, with R&D expenses increasing by 4.36% to 114.43 million RMB, reflecting a commitment to sustainable business growth[68]. - The company launched 18 self-developed projects in the in vitro diagnostic business, obtaining 19 registration certificates, indicating a strong focus on innovation[67]. - The number of R&D personnel increased to 174, accounting for 7.79% of the total workforce[83]. - The company completed 18 out of 42 major stem cell research and product development projects during the reporting period[84]. Market and Industry Trends - The domestic in vitro diagnostic industry is experiencing significant growth, driven by factors such as population aging and rising cancer incidence[43]. - The government has been actively promoting policies to support the development of the stem cell industry, indicating a favorable environment for growth[43]. - The "14th Five-Year Plan" emphasizes biotechnology as a strategic emerging industry, aiming to strengthen the bio-economy and optimize resource allocation for innovation[110]. Risk Factors and Compliance - The company has detailed risk factors that it may face in the report, which investors should review carefully[8]. - The company faces potential risks from industry policies, technology advancements, talent retention, and currency fluctuations, which could impact its operations and financial performance[117]. - The company has established a commitment to fair and transparent governance practices in all related transactions[139]. Environmental Responsibility - The company has implemented a self-monitoring plan for environmental emissions, ensuring compliance with pollution discharge standards[186]. - The company has established an emergency response plan for environmental incidents to minimize potential damage and ensure public safety[185]. - The company’s wastewater discharge met the standards with COD at 96 mg/L, significantly below the limit of 500 mg/L, and no exceedances reported[182]. Shareholder Relations and Commitments - The company has not distributed profits for 2019 and 2020 due to accumulated losses, with a net profit of 6.33 million yuan in 2020[120]. - The company has committed to not engaging in any business that competes with its subsidiaries, ensuring no direct or indirect competition[126]. - The company has established a commitment to avoid any illegal occupation of funds or assets, ensuring compliance with relevant laws and regulations[142].

Financial Performance - The company reported operating revenue of RMB 969.37 million for the first nine months of 2020, a decrease of 3.58% compared to the same period last year[18]. - Net profit attributable to shareholders of the listed company reached RMB 133.10 million, an increase of 42.35% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 52.73 million, down 26.42% from the previous year[18]. - Total operating revenue for Q3 2020 was CNY 349,874,853.88, a 3% increase from CNY 337,027,026.17 in Q3 2019[53]. - Net profit for Q3 2020 reached CNY 52,393,785.04, compared to CNY 32,194,645.05 in Q3 2019, representing a 62.7% increase[57]. - The total comprehensive income for the first three quarters of 2020 was CNY 133,093,977.65, up from CNY 104,980,318.52 in the same period of 2019[57]. - The total comprehensive income attributable to the parent company's owners for the current period is CNY 23,534,610.23, compared to CNY 35,137,921.60 in the same period last year, reflecting a decrease of approximately 33.5%[60]. - The company reported a net loss of ¥450,885,928.09, an improvement from a loss of ¥583,988,877.39 in the previous period[44]. Assets and Liabilities - The total assets of the company at the end of the reporting period were RMB 5.13 billion, reflecting an increase of 4.85% compared to the end of the previous year[18]. - The company’s total equity attributable to shareholders was RMB 3.61 billion, an increase of 7.77% from the end of the previous year[18]. - Total current assets increased to ¥1,942,380,637.21 as of September 30, 2020, up from ¥1,905,868,878.58 on December 31, 2019, representing a growth of 1.9%[38]. - Total non-current assets reached ¥3,183,407,926.35, compared to ¥2,982,669,581.79, reflecting a growth of 6.7%[42]. - Total liabilities decreased slightly to ¥1,400,241,654.71 from ¥1,427,816,142.75, a reduction of 1.9%[44]. - The total cash and cash equivalents at the end of the period amounted to ¥1,010,203,787.47, compared to ¥990,675,535.57 at the end of the same period last year[71]. Cash Flow - The company generated a net cash flow from operating activities of RMB 151.62 million, a decrease of 3.24% compared to the same period last year[18]. - Net cash flow from investing activities increased by 394.26% compared to the same period last year, mainly due to the recovery of structured deposits[33]. - Net cash flow from financing activities decreased by 120.59% compared to the same period last year, primarily due to the absence of funds raised from a previous equity issuance[33]. - The net cash flow from operating activities for the first three quarters of 2020 was ¥151,618,311.80, a decrease from ¥156,699,220.70 in the same period of 2019[71]. - Cash inflow from investment activities reached ¥1,041,263,969.05, significantly higher than ¥16,764,934.16 in the previous year[71]. - The net cash flow from investment activities was ¥306,040,337.65, a recovery from a negative cash flow of ¥104,003,678.31 in the same period of 2019[71]. - The net cash flow from financing activities was -¥72,575,923.72, contrasting with a positive cash flow of ¥352,456,237.59 in 2019[71]. Shareholder Information - The number of shareholders at the end of the reporting period was 31,827[24]. - Shareholders' equity increased to ¥3,725,546,908.85 from ¥3,460,722,317.62, showing a growth of 7.7%[44]. - Basic earnings per share for the current period is CNY 0.11, an increase from CNY 0.07 in the previous quarter, while diluted earnings per share also stands at CNY 0.11[62]. Investment and Expenses - The company confirmed an investment income of RMB 50.07 million from its U.S. subsidiary's investment in Aceso Biotech Venture Fund, L.P.[27]. - Investment income increased by 527.13% compared to the same period last year, primarily due to the recognition of investment income from subsidiaries[32]. - Research and development expenses for Q3 2020 were CNY 38,377,550.11, a 42.6% increase from CNY 26,913,020.93 in Q3 2019[53]. - The company’s long-term investments in equity decreased to ¥213,491,419.30 from ¥220,661,067.04, a decline of 3.9%[38]. - The cash outflow for purchasing fixed assets and intangible assets was ¥75,168,226.98, an increase from ¥54,658,612.47 in the previous year[71]. Other Financial Metrics - The weighted average return on equity increased to 3.85%, up 0.67 percentage points from the previous year[18]. - Other comprehensive income increased by 326.86% compared to the beginning of the year, mainly due to the recognition of fair value changes of investments[31]. - The company reported a gross profit margin of approximately 13.2% for Q3 2020, compared to 11.5% in Q3 2019[53]. - The company experienced a foreign currency translation loss of CNY -15,800,337.66 in the current period, impacting overall comprehensive income[60]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[53]. - The company has not reported any net profit from the merged entity prior to the merger, indicating a focus on future growth opportunities[62]. Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, which are not expected to significantly impact revenue recognition or net profit[76]. - The company did not make retrospective adjustments to prior period financial statements under the new standards[77].

Financial Performance - The company achieved operating revenue of RMB 619.50 million, a decrease of 7.31% compared to the same period last year[21]. - The net profit attributable to shareholders was RMB 81.33 million, an increase of 28.82% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 23.59 million, a decrease of 53.81% compared to the previous year[21]. - The net cash flow from operating activities was RMB 84.58 million, down 9.49% from the same period last year[21]. - The total assets at the end of the reporting period were RMB 5.11 billion, an increase of 4.52% from the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were RMB 3.59 billion, an increase of 7.07% year-on-year[21]. - Basic earnings per share were RMB 0.17, up 21.43% from RMB 0.14 in the same period last year[22]. - The weighted average return on net assets was 2.37%, an increase of 0.13 percentage points compared to the previous year[22]. Investment and Acquisitions - The company recognized an investment income of RMB 50.07 million from its U.S. subsidiary and the acquisition of Zhongyuan Weikang[25]. - The company aims for global expansion through strategic investments and acquisitions, enhancing its operational efficiency and service capabilities[31]. - The company made a significant equity investment of ¥35 million in Heze Biotechnology, acquiring a 100% stake in stem cell storage technology services[61]. - The company reported a profit impact of ¥44.97 million from the sale of its entire stake in Hebecell Corp. to Aceso Biotech Venture Fund, L.P.[67]. - The company’s investment in Aceso Biotech Venture Fund, L.P. was ¥35.40 million, representing a 53.33% equity stake[63]. Research and Development - The company’s R&D expenses increased by 11.47% to ¥54.66 million from ¥49.03 million year-on-year, reflecting a commitment to innovation[47]. - The company has completed six clinical trial registrations for stem cell projects, showcasing its active involvement in advanced medical research[46]. - The company has initiated clinical trials for two new drugs in the immunotherapy sector, indicating progress in its precision treatment initiatives[46]. - The company has established a certain technological lead in cell preservation, separation, and extraction, with several patents obtained and pending, but must continuously invest in R&D to maintain its competitive edge[78]. Market Position and Strategy - The main business focuses on "precision medicine," covering cell detection, preparation, storage, and gene testing services, with significant contributions from stem cell applications[28]. - The company has established a comprehensive cell resource network, serving over 2/3 of the regions and 3/4 of the population in China, enhancing its market presence[31]. - The company emphasizes internal growth and integration of production, research, and sales to improve operational efficiency and innovation[33]. - The company has developed a digital marketing strategy leveraging new media platforms to enhance brand exposure and value[46]. - The company is actively promoting innovative marketing and product development strategies to ensure steady growth[34]. Financial Stability and Risks - The company's trading financial assets decreased by 25.18% to approximately 300.52 million yuan due to the maturity of structured deposits[38]. - Other equity investments increased by 54.00% to approximately 600.94 million yuan, primarily due to fair value changes from overseas investments[38]. - The company faces foreign exchange risks due to its global operations, with sales denominated in multiple currencies, which may impact future financial results[80]. - The company acknowledges the risk of talent shortages and turnover, implementing strategies such as equity incentives and performance-based compensation to align interests and retain key personnel[78]. - The company has committed to closely monitoring national policy developments and adjusting its business and product structures to mitigate potential impacts from regulatory changes[78]. Compliance and Governance - The company reported a significant focus on compliance with legal regulations and corporate governance, emphasizing the protection of minority shareholders' rights[96]. - The company guarantees that any necessary related party transactions will be conducted at fair market prices and in compliance with relevant laws and regulations[92]. - The company has established a framework to address any potential asset impairment issues related to the profit commitments made[89]. - The company has committed to avoiding any form of competition with its subsidiaries, ensuring no similar business activities are conducted that could harm shareholder interests[95]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 32,801[127]. - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 84,064,327 shares, representing 17.96% of total shares[127]. - The total number of shares held by the top ten shareholders includes significant pledges, with Tianjin Development Zone Deyuan Investment having 81,233,260 shares pledged[127]. - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period[133]. Legal Matters - The company has ongoing significant litigation regarding the transfer of state-owned land use rights, with a judgment requiring Singapore Huide Investment Holdings Co., Ltd. to repay CNY 71.21 million[104]. - In a separate case, the company is pursuing enforcement of a civil mediation agreement for a share transfer payment of CNY 30 million, of which only CNY 1 million has been received to date, leaving a balance of CNY 29 million unpaid[104].

Group 1: Event Details - The "Investor Online Reception Day" will be held on June 10, 2020, from 15:00 to 16:30 [1][2] - The event will be conducted online [1][2] Group 2: Company Representatives - Company representatives attending include: - Mr. Wang Yong, Director and General Manager - Mr. Yang Xinzhe, Deputy General Manager and Board Secretary - Mr. Wang Peng, Chief Financial Officer [2] Group 3: Participation Information - Investors can participate by logging into "Panorama · Roadshow World" at http://rs.p5w.net [2] - The company encourages active participation from investors [2]

Financial Performance - The company's audited net profit for 2019 was -58.3992 million RMB, resulting in a cumulative undistributed profit of -233 million RMB as of December 31, 2019, leading to no profit distribution to shareholders [6]. - The total operating revenue for 2019 was approximately 1.387 billion RMB, representing a year-on-year increase of 5.02% compared to 2018 [22]. - The net profit attributable to shareholders of the listed company for 2019 was approximately 49.695 million RMB, a decrease of 16.13% from 2018 [22]. - The net cash flow generated from operating activities for 2019 was approximately 241.49 million RMB, an increase of 85.64% compared to 2018 [25]. - The total assets as of the end of 2019 were approximately 4.889 billion RMB, reflecting a year-on-year increase of 10.02% [25]. - The net assets attributable to shareholders of the listed company at the end of 2019 were approximately 3.354 billion RMB, a 20.96% increase from the end of 2018 [25]. - Basic earnings per share decreased by 26.67% to CNY 0.11 in 2019 compared to CNY 0.15 in 2018 [26]. - The company reported a net profit of approximately 28.438 million RMB after deducting non-recurring gains and losses, a significant improvement compared to a loss of approximately 262.48 million RMB in 2018 [22]. - The company reported a net profit of CNY 30,843,567.35 in Q1 2019, with a decline to -CNY 43,807,553.58 in Q4 2019 [29]. Revenue and Growth - The company achieved a revenue of 1.387 billion, representing a year-on-year growth of 5.02% [61]. - The company reported a total revenue of 109,648,855.89 CNY in R&D investments, accounting for 7.91% of total operating income [76]. - The company reported a significant increase in investment activities cash flow, with a net outflow of RMB 555,140,139.32, a change of -12,968.55% year-over-year [62]. - The company achieved a 66.96% increase in asset disposal income, amounting to 9,997,983.62 CNY, attributed to gains from patent technology disposals [75]. - The company reported a total guarantee amount of 2.17 billion RMB, which accounts for 6.47% of the company's net assets [199]. Research and Development - R&D investment accounted for 7.91% of the company's total revenue in 2019, with 180 R&D personnel [54]. - The company has established a comprehensive industry chain in precision medicine, covering cell storage, gene testing, and in vitro diagnostic reagents [48]. - The company has initiated 28 research projects in Shanghai Zhi Cheng Company, indicating a strong focus on expanding its research capabilities [77]. - The company has established a robust pipeline of diagnostic products, with a focus on immunohistochemistry and related methodologies [99]. - The company’s commitment to research and development is evident in its continuous introduction of new diagnostic reagents throughout the year [100]. Market and Industry Position - The company operates in the fields of cell detection, preparation, storage, and in vitro diagnostic reagents and instruments [35]. - The company aims to expand through both organic growth and strategic acquisitions globally [36]. - The domestic stem cell storage rate is currently below 1%, indicating significant growth potential, with the market size expected to exceed 30 billion RMB [39]. - The sales revenue of in vitro diagnostic reagents in China ranks among the top three in the medical device market, with immunodiagnostics and biochemical diagnostics dominating the market share since 2019 [43]. - The company has established a nationwide stem cell storage network with over 300,000 stored units, covering more than 2/3 of regions and 3/4 of the population in China [38]. Compliance and Governance - The company has established a quality safety management system to prevent potential incidents that could harm its reputation and financial performance [141]. - The company has made commitments to avoid engaging in competitive businesses and to adhere to share lock-up agreements related to major asset restructuring [155]. - The company will ensure compliance with relevant laws and regulations in all transactions to protect the interests of Zhongyuan Hehe and its minority shareholders [161]. - The company has not faced any penalties or corrective actions against its directors, supervisors, or senior management during the reporting period [187]. - The company has not engaged in any undisclosed major related party transactions during the reporting period [191]. Future Plans and Commitments - The company aims to achieve a revenue of 1.482 billion in 2020, focusing on cell storage and in vitro diagnostics as core businesses [137]. - The company plans to enhance its product line by expanding the types of stem cells stored, including hematopoietic stem cells and adipose-derived stem cells [134]. - The company intends to strengthen its online platform for the "life bank," improving user experience and service capabilities [137]. - The company will optimize its management system and organizational structure to improve operational efficiency and reduce costs [137]. - The company is committed to upgrading production processes, including the development of serum-free cell culture systems and automated diagnostic instruments [140].